XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls

World J Gastroenterol. 2011 May 14;17(18):2343-8. doi: 10.3748/wjg.v17.i18.2343.

Abstract

Aim: To evaluate the association between xeroderma pigmentosum group D (XPD), genetic polymorphism Lys751Gln and esophageal cancer risk.

Methods: We searched PubMed up to September 1, 2010 to identify eligible studies. A total of 10 case-control studies including 2288 cases and 4096 controls were included in the meta-analysis. Statistical analysis was performed with Review Manage version 4.2. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association.

Results: The results suggested that there is no significant association between XPD Lys751Gln polymorphism and esophageal cancer susceptibility in the overall population. However, in subgroup analysis by histology type, a significant association was found between XPD Lys751Gln polymorphism and esophageal adenocarcinoma (for CC vs AA: OR = 1.25, 95% CI = 1.01-1.55, P = 0.05 for heterogeneity).

Conclusion: Our meta-analysis suggested that XPD Lys751Gln polymorphism may be associated with increased risk of esophageal adenocarcinoma.

Keywords: Esophageal cancer; Mwta-analysis; Polymorphism; Xeroderma pigmentosum group D.

Publication types

  • Meta-Analysis

MeSH terms

  • Adenocarcinoma / genetics*
  • Case-Control Studies
  • Esophageal Neoplasms / genetics*
  • Humans
  • Polymorphism, Single Nucleotide*
  • Risk Assessment
  • Xeroderma Pigmentosum Group D Protein / genetics*

Substances

  • Xeroderma Pigmentosum Group D Protein
  • ERCC2 protein, human